Investment Analysts’ Recent Ratings Updates for Climb Bio (CLYM)

A number of research firms have changed their ratings and price targets for Climb Bio (NASDAQ: CLYM):

• 10/20/2026 – Climb Bio is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $28.00 price target on the stock.
• 10/15/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Climb Bio had its “buy” rating reaffirmed by HC Wainwright.
• 10/5/2026 – Climb Bio had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $34.00 price target on the stock.
• 10/3/2026 – Climb Bio was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/16/2026 – Climb Bio was upgraded by Mizuho to “strong-buy”.
• 9/8/2026 – Climb Bio had its price target raised by Oppenheimer from $18.00 to $25.00. They now have an “outperform” rating on the stock.
• 9/8/2026 – Climb Bio had its price target raised by HC Wainwright from $24.00 to $30.00. They now have a “buy” rating on the stock.
• 9/7/2026 – Climb Bio was upgraded by Mizuho to “strong-buy”.
• 9/4/2026 – Climb Bio had its “buy” rating reaffirmed by B. Riley Financial.
• 9/4/2026 – Climb Bio had its “buy” rating reaffirmed by B. Riley Financial. They now have a $30.00 price target on the stock, up from $26.00.
• 9/3/2026 – Climb Bio was given a new $40.00 price target by Piper Sandler. They now have an “overweight” rating on the stock.
• 9/3/2026 – Climb Bio had its price target raised by Robert W. Baird from $21.00 to $25.00. They now have an “outperform” rating on the stock.
• 9/3/2026 – Climb Bio had its price target raised by BTIG Research from $20.00 to $32.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Climb Bio had its price target raised by HC Wainwright from $20.00 to $24.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In related news, Director Stephen Thomas sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total value of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at approximately $6,397,136.23. This represents a 17.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.60% of the company’s stock.

Climb Bio, Inc (NASDAQ: CLYM) is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company is working to create medicines that target B cells, which play a central role in the immune responses associated with many autoimmune disorders.

Climb Bio’s lead investigational product, CLYM116, is a fully human anti-CD19 monoclonal antibody designed to selectively deplete B cells. The therapy is being evaluated in clinical development for autoimmune conditions, including primary membranous nephropathy, a kidney disorder in which abnormal immune activity can damage the kidneys.

As a development-stage biotechnology company, Climb Bio’s activities are centered on research, clinical trials and the potential commercialization of its pipeline rather than on marketed products.